BNIP3 and ovarian carcinoma: Higher levels of BNIP3 in samples isolated from ovarian cancer patients (treated with carboplatin together with doxorubicin or taxol) were associated with reduced survival, suggesting a role for BNIP3 in platinum-related resistance mechanism (Fig. 3J, K).